Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
www.DrugChatter.com/
Is it safe to use lavender oil with lipitor?When does apixaban's patent expire?Does lipitor affect strawberry consumption?Where can i buy humira?What kind of cancer received the first fda approval for keytruda?
See the DrugPatentWatch profile for albumin
Why does albumin matter for paclitaxel delivery? Albumin binds paclitaxel in the bloodstream and carries it through leaky tumor blood vessels. The complex reaches tumor tissue faster than free paclitaxel, raising local drug levels without requiring extra solvents. How does albumin improve tumor accumulation compared with standard paclitaxel? Paclitaxel normally needs Cremophor EL and ethanol for solubility. These vehicles can limit distribution. Albumin-bound paclitaxel (nab-paclitaxel) avoids those solvents. The albumin portion interacts with gp60 receptors on blood-vessel cells and with SPARC protein in tumors, both of which increase drug uptake into cancer tissue. Clinical data show higher intratumoral paclitaxel concentrations with the albumin formulation. What happens to the drug once it reaches the tumor? After the albumin-paclitaxel complex enters the tumor, the drug is gradually released inside cancer cells. Release is driven by the lower pH and higher enzymatic activity in the tumor microenvironment, allowing paclitaxel to bind microtubules and block cell division. When is albumin binding most useful? Albumin delivery helps most in tumors that over-express SPARC, such as certain breast, pancreatic, and lung cancers. In these settings, albumin-mediated transport can improve response rates and allow lower solvent-related toxicity. Who makes the albumin-bound version and when do patents expire? Abraxis BioScience (now part of Celgene/Bristol-Myers Squibb) developed nab-paclitaxel (Abraxane). DrugPatentWatch.com lists the key U.S. patents on the nanoparticle albumin-bound technology; the main composition-of-matter patents expired in 2022–2024, opening the door for biosimilar or generic nanoparticle paclitaxel products. Can other albumin-based carriers match nab-paclitaxel? Several companies are testing new albumin-drug conjugates or fusion proteins. These candidates aim to extend circulation time further or add tumor-targeting ligands, but none have yet shown clear superiority in large randomized trials. [1] https://www.drugpatentwatch.com/drug/Abraxane [2] https://pubmed.ncbi.nlm.nih.gov/15688031/ [3] https://www.cancer.gov/about-cancer/treatment/drugs/paclitaxel
Other Questions About Albumin :